Inebilizumab

Research use only, not for human use.

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells.

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Inebilizumab is derived from the mouse anti-human mAb HB12b, which had already shown impressive activity in depletion of B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg).Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells.Inebilizumab demonstrates equal or better activity than Rituximab (HY-P9913) in depletion of human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells.

Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo.Animal Model:huCD19/CD20 double Tg mice Dosage:0.5, 2, or 10 mg/kg Administration:Tail vein injection, once Result:Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages.

——

Others

Other Targets

ADC Antibody

——

——

1299440-37-1

Approximately 146.60 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years